Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable respon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results